NSCALE/KONTENA
22.7.2024 03:45:01 CEST | Business Wire | Press release
Nscale, a fully vertically integrated AI cloud platform, today announced the acquisition of Kontena, a leader in high-density modular data centres and AI Data Centre solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721172829/en/
Joshua Payne, Founder and CEO, Nscale (Photo: Business Wire)
This acquisition marks a significant step forward in Nscale's mission to provide the infrastructure backbone to the growing generative AI market through cost-effective, high-performance solutions that unlock AI's full potential.
Jef Laurijssen, CEO of Kontena, commented: “Joining forces with Nscale provides us with an incredible opportunity to accelerate the development and deployment of cutting-edge Generative AI Data Centre solutions. Our combined expertise will enable us to deliver unparalleled value to our customers in the AI and HPC markets.”
Capitalising on Kontena’s innovative KONNECT ecosystem combined with Nscale’s extensive infrastructure capabilities, the two companies will deliver high-performance solutions. Kontena's flagship product, the EDGE data room, is a fully modular Generative AI Data Centre solution designed to meet the complex demands of advancing AI development. The EDGE data room is one of the world’s first modular solution deploying AI infrastructure on-premises and in remote locations, far quicker and at lower cost than traditional Tier 3 Data Centres.
Nscale’s acquisition of Kontena bolsters its commitment to sustainability. Kontena’s modular AI data centre solutions will enable Nscale to deliver faster and more cost-effective deployments for customers at its 100% renewable data centre sites in Norway and the US.
Joshua Payne, CEO of Nscale, commented: “The acquisition of Kontena allows Nscale to design, build, and deploy bespoke GPU clusters at scale for global Generative AI customers more quickly and more cost-effectively than the competition. Building Kontena into the Nscale value chain will allow us to deliver bespoke GPU superclusters and data centre builds for our large supercluster and hyperscale customers across Nscale’s 500MW of greenfield data centre capacity. This modular system can be deployed in Nscale’s data centres, on-premise, or at the edge to deliver unrivalled speed, performance, and efficiency on GenAI workloads. This is an important step towards our goal of vertical integration.”
This acquisition underscores Nscale’s dedication to driving innovation and delivering exceptional value to its customers. It follows Nscale’s recent announcement of a strategic partnership with Open Innovation AI, a leading GPU orchestration platform in MENA, targeting the deployment of 30,000 GPUs over the next 3 years, further solidifying its commitment to AI infrastructure and optimised workloads for global markets.
About Nscale
Nscale is a fully vertically integrated AI GPU Cloud provider delivering compute to the generative AI market at scale. Leveraging its 60MW renewable energy-powered data centre in Norway and a pipeline of over 500MW of greenfield data centres in the US. Nscale enables customers to run efficient and scalable AI training, fine-tuning, and compute-intensive workloads, supporting advanced AI research and development. Nscale provides the AI infrastructure backbone to the generative AI market.
About Kontena
Founded in 2018, Kontena specialises in high-density data centres and HPC solutions, combining innovation with practicality. The company recently collaborated with ElioVP and Bluesio to develop better and more innovative AI and HPC solutions.
For more information about Nscale’s AI & HPC solutions and the Kontena acquisition, visit nscale.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240721172829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom